Role of B7-H3 in predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.

Autor: Deol ES; Department of Urology Mayo Clinic Rochester Minnesota USA., Nabavizadeh R; Department of Urology Mayo Clinic Rochester Minnesota USA., Lavoie RR; Department of Urology Mayo Clinic Rochester Minnesota USA., Dumbrava MG; Division of Experimental Pathology Mayo Clinic Rochester MN., Horjeti E; Department of Urology Mayo Clinic Rochester Minnesota USA., Thapa P; Department of Urology Mayo Clinic Rochester Minnesota USA., Cheville JC; Division of Experimental Pathology Mayo Clinic Rochester MN.; Department of Pathology and Laboratory Medicine Mayo Clinic Rochester Minnesota USA., Frank I; Department of Urology Mayo Clinic Rochester Minnesota USA., Lucien F; Department of Urology Mayo Clinic Rochester Minnesota USA.
Jazyk: angličtina
Zdroj: BJUI compass [BJUI Compass] 2024 Sep 11; Vol. 5 (11), pp. 1052-1058. Date of Electronic Publication: 2024 Sep 11 (Print Publication: 2024).
DOI: 10.1002/bco2.418
Abstrakt: Background: Neoadjuvant platinum-based chemotherapy offers a modest survival advantage in muscle-invasive bladder cancer (MIBC) for patients with pathologic response. B7-H3 ( CD276 ), an immune checkpoint overexpressed in various cancers, including urothelial-cell carcinoma (UCC), has been associated with chemoresistance and poor oncologic outcomes. We aimed to explore if B7H3 expression on bladder biopsy samples was a predictive biomarker for pathologic response to neoadjuvant platinum-based chemotherapy.
Methods: This was a retrospective cohort study among MIBC patients receiving neoadjuvant platinum-based chemotherapy followed by radical cystectomy. All patients underwent routine preoperative biopsy of their tumour. Immunohistochemistry was used to evaluate B7-H3 expression from pre-operative specimens. The primary outcome of interest was pathologic complete response (pCR). Statistical analysis included Mann-Whitney U test, Fisher's exact test, Kaplan-Meier method, and Cox regression for survival analysis.
Results: Among 87 patients analysed, high B7-H3 expression was found in 44.8% ( n  = 39) of patients. The median follow-up periods were similar between the high and low B7-H3 groups (high expression; 4.29 years [SD 3.04], low expression 3.94 years [SD 3.04], p  = 0.60). Only 20.5% of patients with high B7-H3 expression achieved pCR, compared to 41.7% in the low expression group ( p  = 0.04). Cox regression showed no significant differences in recurrence-free or cancer-specific survival between the high and low B7-H3 expression groups ( p  > 0.05).
Conclusion: High B7-H3 expression is associated with a reduced likelihood of achieving pCR in MIBC patients undergoing neoadjuvant chemotherapy. This suggests B7-H3's potential as a predictive biomarker for chemotherapy response. Further research is needed to explore the role of B7-H3 on platinum-based chemotherapy response in urothelial cancer.
Competing Interests: The authors have nothing to disclose.
(© 2024 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.)
Databáze: MEDLINE
Externí odkaz: